All In Biotech

NDA 020472 · Pfizer

Estring

Estradiol · Vaginal · Estrogen

Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Apr 26, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,701

351 Phase 3, 176 recruiting

FAERS reports

51,271

23,952 serious, 962 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 23, 2026.

INDICATIONS AND USAGE ESTRING is indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 26, 1996 Original approval · Type 3 - New Dosage Form Letter
1 products under this application
  • ESTRING · ESTRADIOL 0.0075MG/24HR · INSERT, EXTENDED RELEASE, VAGINAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.

All 1,701 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,432
  • headache3,031
  • nausea3,016
  • fatigue2,960
  • off label use2,654
  • pain2,248
  • diarrhoea2,028
  • dizziness1,810
  • breast cancer female1,728
  • arthralgia1,698
  • pruritus1,630
  • rash1,602

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004536
2005588
2006416
20071,480
2008452
2009631
20101,279
20111,021
20121,340
20131,164
20141,363
20152,197
20162,618
20172,382
20182,712
20193,141
20203,152
20213,116
20223,336
20233,844
20243,943
20255,422
20265,137

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Estring (Estradiol)

2024 spending

$49.2M

Beneficiaries

33,078

90,750 claims

Per beneficiary

$1,487

$539.53 per unit

View as table
YearSpending
2020$42,668,879
2021$47,020,494
2022$50,418,584
2023$50,334,382
2024$49,188,152

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,476 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.